Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Salt pills could boost heart failure treatment, small trial hints

NCT ID NCT04334668

Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether giving oral salt tablets alongside standard IV diuretics helps hospitalized heart failure patients lose more fluid and maintain better kidney function. About 67 adults with acute decompensated heart failure will receive either salt or placebo three times daily for about 4 days. The goal is to see if this simple addition improves weight loss and creatinine levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral sodium chloride (table salt)
What this could lead to
If it works, this could point toward a simple, low-cost way to improve fluid removal and protect kidneys during heart failure treatment.
What could go wrong
This is a small, early-phase study with only 67 participants, so results may not apply broadly. Adding salt could also worsen fluid overload in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

67 people

The number who actually took part.

Started

May 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old AND * Admitted to cardiology floor (non-ICU) with primary diagnosis of decompensated heart failure AND * NT-proBNP \>1000 ng/L AND * Initiation of continuous furosemide infusion at a rate of 10 mg/hr or higher Exclusion Criteria: * Serum sodium (Na+) level less than 120 or greater than 145. * Average Systolic Blood Pressure \>180 mmHg or Diastolic Blood Pressure \>100 mmHg over past 24 hours. * Anticipated length of stay less than 72 hours. * Use of vasopressin antagonist * Current use of sodium chloride tablets * Active diagnosis of diabetes insipidus * Inability to tolerate oral diet or swallow pills * Presence of malabsorptive gastrointestinal disorder (Crohn's disease, short gut syndrome) * The use of iodinated radiocontrast material in the past 72 hours or anticipated use of intravenous contrast during the current hospitalization * Admission with intention to transplant or implant permanent Ventricular Assistive Device * Use of intravenous inotropes, vasopressors or vasodilators at enrollment * A baseline estimated glomerular filtration rate \<15 mL/min/1.73m² according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at the moment of inclusion * Use of renal replacement therapy at time of enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure Edema heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Volume overload

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.